Benefits of Gender-Neutral Vaccination Strategy for the Prevention of HPV-Associated Diseases and the Eradication of HPV Infection in General. Current State of HPV Vaccination in the World
https://doi.org/10.15690/pf.v18i3.2285
Abstract
Papillomavirus infection (HPV infection) is the leading sexually transmitted infection in prevalence. HPV infection and associated diseases, including cancer, remain one of the global problems of our time. This literature review presents relevant data from foreign studies and domestic works on the state of HPV vaccination in the world, the modern vaccines efficacy for the HPV-associated diseases prevention, current vaccination strategies and their efficacy as well. The aim of the article is to determine the advantages of using gender-neutral vaccination strategy over priority-used vaccination strategy for girls only in the prevention of HPV-associated diseases, including cancer, as well as for eradicating HPV infection in general.
Keywords
human papillomavirus,
HPV-associated diseases,
vaccination,
vaccination strategies,
gender-neutral vaccination
Supporting agencies: Not specified
About the Authors
Tatiana E. Privalova
Pirogov Russian National Research Medical University; Research Institute of Pediatrics and Children's Health in Central Clinical Hospital of the Russian Academy of Sciences
Russian Federation
Disclosure of interest:
Russian Federation
MD, PhD, eLibrary SPIN: 7879-4299
10 Fotievoy street, 119333, Moscow
Disclosure of interest:
receiving fees from pharmaceutical companies “MSD Pharmaceuticals”, “Bionorica”, “Nutricia”
Olga V. Surovtseva
Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
1 Ostrovityanova street, 117997, Moscow
Disclosure of interest:
confirmed the absence of a reportable conflict of interests
Dmitry V. Andriyanov
Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
1 Ostrovityanova street, 117997, Moscow
Disclosure of interest:
confirmed the absence of a reportable conflict of interests
References
1. Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3-12. doi: 10.1016/j.mrrev.2016.07.002
2. Bacaj P, Burch D. Human Papillomavirus Infection of the Skin. Arch Pathol Lab Med. 2018;142(6):700-705. doi: 10.5858/arpa.2017-0572-RA
3. Luria L, Cardoza-Favarato G. Human Papillomavirus. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 24, 2021. Available online: https://www.statpearls.com/ArticleLibrary/viewarticle/23034. Accessed on July 6, 2021.
4. Steinbach A, Riemer AB. Immune evasion mechanisms of human papillomavirus: An update. Int J Cancer. 2018;142(2):224-229. doi: 10.1002/ijc.31027
5. Egawa N, Egawa K, Griffin H, Doorbar J. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia. Viruses. 2015;7(7):3863-3890. doi: 10.3390/v7072802
6. Bravo IG, Felez-Sanchez M. Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health. 2015;2015(1):32-51. doi: 10.1093/emph/eov003
7. Nunes EM, Talpe-Nunes V, Sichero L. Epidemiology and biology of cutaneous human papillomavirus. Clinics (Sao Paulo). 2018;73(Suppl 1):e489s. doi: 10.6061/clinics/2018/e489s
8. Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017;231:119-127. doi: 10.1016/j.virusres.2016.12.017
9. Papillomavirus Episteme (PaVE): A resource of the Bioinformatics and Computational Biosciences Branch at the National Institute of Allergy and Infectious Diseases (NIAID) Office of Cyber Infrastructure and Computational Biology. Available online: https://pave.niaid.nih.gov. Accessed on March 30, 2021.
10. Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical Cancer Screening: Past, Present, and Future. Sex Med Rev. 2020;8(1):28-37. doi: 10.1016/j.sxmr.2019.09.005
11. Kobayashi K, Hisamatsu K, Suzui N, Hara A, Tomita H, Miyazaki T. A Review of HPV-Related Head and Neck Cancer. J Clin Med. 2018;7(9):241. doi: 10.3390/jcm7090241
12. Timbang MR, Sim MW, Bewley AF, Farwell DG, Mantravadi A, Moore MG. HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccin Immunother. 2019;15(7-8):1920-1928. doi: 10.1080/21645515.2019.1600985
13. Spence T, Bruce J, Yip KW, Liu FF. HPV Associated Head and Neck Cancer. Cancers (Basel). 2016;8(8):75. doi: 10.3390/cancers8080075
14. Bratman SV, Bruce JP, O'Sullivan B, et al. Human Papillomavirus Genotype Association With Survival in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2016;2(6):823-826. doi: 10.1001/jamaoncol.2015.6587
15. Wittekindt C, Wagner S, Sharma SJ, et al. HPV — A different view on Head and Neck Cancer. Laryngorhinootologie. 2018;97(S 01):S48-S113. doi: 10.1055/s-0043-121596
16. Stratton KL, Culkin DJ. A Contemporary Review of HPV and Penile Cancer. Oncology (Williston Park). 2016;30(3):245-249.
17. Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer. 2017;123(12):2219-2229. doi: 10.1002/cncr.30588
18. Ilboudo M, Zohoncon TM, Traore IMA, et al. Implication of low risk human papillomaviruses, HPV6 and HPV11 in laryngeal papillomatosis in Burkina Faso. Am J Otolaryngol. 2019;40(3):368-371. doi: 10.1016/j.amjoto.2019.02.003
19. National Cancer Institute. The Surveillance, Epidemiology, and End Results (SEER). Available online: https://seer.cancer.gov/statistics. Accessed on March 30, 2021.
20. World Health Organization International Agency for Research on Cancer. Global Cancer Observatory. Available online: https://gco.iarc.fr. Accessed on March 30, 2021.
21. Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in Human Papillomavirus-Associated Cancers — United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2018;67(33):918-924. doi: 10.15585/mmwr.mm6733a2
22. World Health Organization. Recomendations for routine immunization (updated: September 2020) Available online: http://www.who.int/immunization/policy/Immunization_routine_table1.pdf Accessed on February 20, 2021.
23. Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives. J Oncol. 2019;2019:3257939. doi: 10.1155/2019/3257939
24. Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36(32 Pt A):4768-4773. doi: 10.1016/j.vaccine.2017.12.079
25. Stanley M, Dull P HPV single-dose vaccination: Impact potential, evidence base and further evaluation. Vaccine. 2018;36(32 Pt A):4759-4760. doi: 10.1016/j.vaccine.2018.02.076
26. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5(0 5):F123-F138. doi: 10.1016/j.vaccine.2012.04.108
27. Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine trials and tribulations: Vaccine efficacy. J Am Acad Dermatol. 2015;73(5):759-768. doi: 10.1016/j.jaad.2015.05.041
28. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-723. doi: 10.1056/NEJMoa1405044
29. Vesikari T, Brodszki N, van Damme P, et al. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Pediatr Infect Dis J. 2015;34(9):992-998. doi: 10.1097/INF.0000000000000773
30. Nyg rd M, Saah A, Munk C, et al. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin Vaccine Immunol. 2015;22(8):943-948. doi: 10.1128/CVI.00133-15
31. Brotherton JML. Impact of HPV vaccination: Achievements and future challenges. Papillomavirus Res. 2019;7:138-140. doi: 10.1016/j.pvr.2019.04.004
32. Expert Council Resolution “Human Papillomavirus Infection: a Review of Experience in Solving a Multidisciplinary Problem”. Epidemiology and Vaccinal Prevention. 2018;17(6):109-113. (In Russ).
33. Tanaka H, Shirasawa H, Shimizu D, et al. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women. J Obstet Gynaecol Res. 2017;43(10):1597-1601. doi: 10.1111/jog.13419
34. World Health Organization. Progress and Challenges with Achieving Universal Immunization Coverage 2019 (data as July 2020). Available online: https://www.who.int/immunization/moni-toring_surveillance/who-immuniz.pdf. Accessed on February 20, 2021.
35. Sheikh S, Biundo E, Courcier S, et al. A report on the status of vaccination in Europe [published correction appears in Vaccine. 2019 Feb 28;37(10):1374-1376]. Vaccine. 2018;36(33):4979-4992. doi: 10.1016/j.vaccine.2018.06.044
36. Toh ZQ, Russell FM, Garland SM, Mulholland EK, Patton G, Licciardi PV. Human Papillomavirus Vaccination After COVID-19. JNCI Cancer Spectr. 2021;5(2):pkab011. doi: 10.1093/jncics/pkab011
37. Gavi. Overview of COVID-19 Situation in GAVI-Supported Countries and GAVI’s Response 30th June 2020. Available online: https://www.gavi.org/vaccineswork/30-june-2020-overview-covid-19-situation-gavi-supported-countries-gavi-response. Accessed on March 30, 2021.
38. Devyatilova AN. Possibilities of prevention and early diagnosis of cervical cancer at the regional level. Smolensk medical almanac. 2019;(1):95-97. (In Russ).
39. Simakhodsky AS, Ippolitova MF. Experience of Formation and Implementation of the Regional Program of Immunization of Children's Population of St. Petersburg against Papillomavirus Infection. Epidemiology and Vaccinal Prevention. 2019;18(3):65-70. (In Russ). doi: 10.31631/2073-3046-2019-18-3-65-70
40. Filippov OV, Bolshakova LN, Elagina TN, Novikova YuB., Shapovalova RF, Aristova AM. Regional Schedule of Vaccination in Moscow: History, Development, Prospects. Epidemiology and Vaccinal Prevention. 2020;19(4):63-75. (In Russ). doi: 10.31631/2073-3046-2020-19-4-63-75
41. Williams WW, Lu PJ, O'Halloran A, et al. Surveillance of Vaccination Coverage among Adult Populations — United States, 2015. MMWR Surveill Summ. 2017;66(11):1-28. doi: 10.15585/mmwr.ss6611a1
42. Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland. Vaccine. 2018;36(39):5926-5933. doi: 10.1016/j.vaccine.2018.06.074
43. Public Health England. Human papillomavirus (HPV) vaccination coverage in adolescent females in England: 2018/19: Report for England. Avaliable online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/851797/HPV_annual_coverage_report_2018_to_2019.pdf. Accessed on March 30, 2021.
44. Walker TY, Elam-Evans LD, Yankey D, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years — United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718-723. doi: 10.15585/mmwr.mm6833a2
45. Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015;350:h2016. doi: 10.1136/bmj.h2016
46. Vanska S, Luostarinen T, Baussano I, et al. Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. J Infect Dis. 2020;222(6):948-956. doi: 10.1093/infdis/jiaa099
47. Faust H, Toft L, Sehr P, et al. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559-1565. doi: 10.1016/j.vaccine.2016.02.019
48. Lehtinen M, Luostarinen T, Vanska S, et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). Int J Cancer. 2018;143(9):2299-2310. doi: 10.1002/ijc.31618
49. Drolet M, Benard Ё, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-580. doi: 10.1016/S1473-3099(14)71073-4
50. Cameron RL, Kavanagh K, Pan J, et al. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013. Emerg Infect Dis. 2016;22(1):56-64. doi: 10.3201/eid2201.150736
51. Brisson M, Benard Ё, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8-e17. doi: 10.1016/S2468-2667(16)30001-9
52. Elfstrom KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human Papillomavirus Vaccination of Boys and Extended Catchup Vaccination: Effects on the Resilience of Programs. J Infect Dis. 2016;213(2):199-205. doi: 10.1093/infdis/jiv368
53. Chow EPF, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study [published correction appears in Lancet Infect Dis. 2017 Jan;17 (1):17]. Lancet Infect Dis. 2017;17(1):68-77. doi: 10.1016/S1473-3099(16)30116-5
54. Spinner C, Ding L, Bernstein DI, et al. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. Pediatrics. 2019;143(2):e20181902. doi: 10.1542/peds.2018-1902
55. Machalek DA, Chow EP Garland SM, et al. Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program. J Infect Dis. 2017;215(2):202-208. doi: 10.1093/infdis/jiw530
56. Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293-1302. doi: 10.1016/S1473-3099(17)30468-1
57. Novakovic D, Cheng ATL, Zurynski Y, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis. 2018;217(2):208-212. doi: 10.1093/infdis/jix498
58. Lehtinen M, Soderlund-Strand A, Vanska S, et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). Int J Cancer. 2018;142(5):949-958. doi: 10.1002/ijc.31119
Review
For citations:
Privalova T.E., Surovtseva O.V., Andriyanov D.V. Benefits of Gender-Neutral Vaccination Strategy for the Prevention of HPV-Associated Diseases and the Eradication of HPV Infection in General. Current State of HPV Vaccination in the World. Pediatric pharmacology. 2021;18(3):239-244. (In Russ.) https://doi.org/10.15690/pf.v18i3.2285
Views:
652
Email this article 